New hope for malaria patients with G6PD deficiency?

NCT ID NCT07468513

Recruiting now Disease control Sponsor: Menzies School of Health Research Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how safe and effective primaquine is for treating vivax malaria in people with intermediate or deficient G6PD enzyme levels. About 100 adults with confirmed malaria and G6PD deficiency will receive either a high daily dose or a weekly dose of primaquine. The goal is to find a treatment that works without causing serious side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VIVAX MALARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

G6PD deficiency Plasmodium vivax malaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

G6PD DEFICIENCY VIVAX MALARIA

Contacts and locations

Show contact details

Locations

Arba Minch General Hospital
NOT_YET_RECRUITING

Arba Minch, Ethiopia

Contact Phone: •••-•••-•••• Email: •••••@•••••
Dr Marcus Lacerda
RECRUITING

Manaus, Brazil

Contact Phone: •••-•••-•••• Email: •••••@•••••
Dr Moses Laman and Dr Brioni Moore
RECRUITING

Alexishafen, Madang Province, Papua New Guinea

Contact Phone: •••-•••-•••• Email: •••••@•••••
Papua New Guinea Institute of Medical Research
RECRUITING

Port Moresby, Magang, Papua New Guinea

Contact Phone: •••-•••-•••• Email: •••••@•••••